MMP-2 binding to ␣v␤3, while this quantity of FHEX did not ( Figure 1C ). These data demonstrate that PEX can interact with ␣v␤3 and prevent MMP-2 binding to this integrin. Interestingly, when this hemopexin domain is expressed in the context of the hinge region and an adjacent fibronectin type II repeat (FHEX), its ability to interact with ␣v␤3 is significantly diminished. These findings suggest that the hemopexin-like domain of MMP-2 can interact with ␣v␤3 and that this interaction may be structurally influenced by regions outside the hemopexin domain. In any event, FHEX proved to be a useful control fusion protein for these studies as it contains the hemopexin domain yet fails to significantly interact with ␣v␤3.
PEX Blocks Cell-Mediated Collagen Degradation
Expression of ␣v␤3 on the surface of invasive cells can facilitate cell surface localization of MMP-2 and thus potentiate cell-mediated collagen degradation (Brooks et al., 1996) . To examine the effects of PEX on celldirected collagenolytic activity, we examined ␣v␤3-bearing melanoma and endothelial cells, which produce only minimal quantities of endogenous MMP-2 (data not shown). CS-1 melanoma cells lack expression of integrin ␣v␤3. These cells were transfected with a cDNA encoding the ␤3 integrin subunit that facilitates functional expression of ␣v␤3 (Filardo et al., 1995) . Full-length MMP-2 was then incubated with either ␣v␤3-negative CS-1 cells or CS-1 cells that express ␣v␤3, in the presence or absence of either PEX or FHEX. As shown in Figure 2A , addition of MMP-2 to ␣v␤3-expressing CS-1 cells, but not control cells, resulted in a dramatic increase in collagenolytic activity that was inhibited by the addition of PEX, but not FHEX. In contrast, both ␣v␤3-negative and ␣v␤3-positive CS-1 cells showed only minimal collagenolytic activity in the absence of exogenously added MMP-2. These findings demonstrate that expression of integrin ␣v␤3 on CS-1 melanoma cells promotes cell 
sorting (FACS), facilitating the selection of a stable ␣v␤3
Fusion protein PEX encodes the hemopexin-like domain alone negative nonclonal endothelial cell variant. Importantly, (amino acids 445-637) , while fusion protein FHEX encodes the heneither the ␣v␤3-positive nor the ␣v␤3-negative cells mopexin domain as well as the hinge region and the third of the three produced significant levels of endogenous MMP-2, and fibronectin type II repeats, encompassing amino acids 292-637. both cell variants showed identical integrin profiles with (B) Dose response binding curve for fusion proteins PEX and FHEX the exception of integrin ␣v␤3 (data not shown). As to purified integrin ␣v␤3. The recombinant fusion proteins PEX and shown in Figure 2B , only the ␣v␤3-bearing endothelial FHEX were radioiodinated and allowed to interact with immobilized integrin ␣v␤3 in a purified receptor binding assay as described in cells showed a significantly increased collagenolytic acthe Experimental Procedures. tivity after incubation with exogenously added MMP-2.
(C) Radiolabeled full-length MMP-2 was allowed to interact with This cell-mediated collagenolytic activity could be repurified immobilized integrin ␣v␤3 in the presence or absence of duced by preincubation of these cells with PEX but was 100-fold molar excess of unlabeled PEX or FHEX. Data represents only minimally affected by FHEX ( Figure 2B ). This sugthe mean Ϯ standard error from triplicate wells.
gests that addition of PEX to ␣v␤3-expressing cells can prevent MMP-2 binding to the cell surface, thereby deonto microtiter wells and allowed to interact with radiolacreasing cell-mediated collagenolytic activity. beled PEX or FHEX. As shown in Figure 1B , PEX readily bound to integrin ␣v␤3 in a dose-dependent manner, Detection of Autocatalytically Derived PEX while FHEX showed only minimal binding. The specificity
In Vitro and In Vivo of this interaction was further demonstrated since a 100-MMP-2 activity has been suggested to play a critical role in angiogenesis since inhibitors of this enzyme block fold molar excess of unlabeled PEX competed for intact MMP-2 processing was examined in vitro in response to organomer␣v␤3-positive and -negative variants of CS-1 melanoma cells and curial activation and in vivo via tumor-associated degradation of ECV304 endothelial cells were isolated as described in the Experiendogenous MMP-2. Autocatalytically derived C-terminal fragment mental Procedures. These cell variants of both cell types produce was purified and assessed for its ability to inhibit interaction beminimal quantities of endogenous MMP-2. Full-length recombinant tween the full-length enzyme and integrin ␣v␤3. MMP-2 was allowed to bind to these cells in the presence or absence (A) Intact purified chick MMP-2 was activated with APMA, and equal of either PEX or FHEX, followed by washing to remove unbound quantities of starting material or activated MMP-2 were electrophoenzyme and seeding into microtiter wells coated with [ 3 H]-collagen resed and analyzed by Western blotting with an anti-MMP-2 polytype IV. Substrate degradation was assessed as the release of raclonal antibody. diolabled material into the culture medium after 36 hr. Data bars (B) ELISA determination of autocatalytically derived C terminus efrepresent the mean Ϯ standard error of corrected cpm from triplicate fect on MMP-2 binding to integrin ␣v␤3. Full-length purified MMP-2 wells. Cell-mediated collagen degradation by (A) CS-1 melanoma was allowed to interact with integrin ␣v␤3 in the presence or absence cells or (B) ECV304 endothelial cells. In a typical experiment, the of increasing concentrations of C terminus purified from activated collagenase activity was 2-3 fold over background levels. intact enzyme. Data points indicate the background-corrected mean Ϯ standard errors from triplicate wells.
neovascularization (Moses et al., 1990; Galardy et al., 1994; Anand-Apte et al., 1997) . Activation of MMP-2 recombinant PEX. Importantly, the accumulation of the C-terminal fragment increased significantly after activadepends on its proteolytic processing. In fact, proteolytic removal of the N-terminal 80-amino acid prodomain tion with APMA (data not shown). These findings demonstrate that PEX is a natural breakdown product of this of MMP-2 leads to the generation of a 62 kDa active form (Ward et al., 1991; Fridman et al., 1992; Strongin enzyme. To establish whether an autocatalytically generated et al., 1995), which can be processed further to a 43 kDa fragment with gelatinolytic activity and a noncatalytic 29 C terminus of MMP-2 might display similar properties to those observed for the recombinant form of this protein, kDa C-terminal fragment, which comprises the hemopexin-like domain (Howard et al., 1991) . As shown in solid-phase receptor binding analyses were performed. As shown in Figure 3B , the MMP-2 C terminus derived Figure 3A , purified MMP-2 can be activated in vitro with p-aminophenyl-mercuric acetate (APMA), which leads from the intact purified enzyme inhibits the interaction between ␣v␤3 and MMP-2 in a dose-dependent manner. to the generation of the 62 kDa active species and the C-terminal fragment as detected by immunoblotting. In
The specificity of this interaction was further demonstrated since neither full-length MMP-9 nor glutathioneaddition, the 43 kDa gelatinolytic fragment can be detected by zymography, but due to its rapid processing S-transferase at equimolar concentrations interfered with intact MMP-2 binding to ␣v␤3 (data not shown). this fragment appears only as a transient breakdown product (data not shown). Interestingly, the C-terminal fragment as well as the proenzyme and active forms Naturally Occurring PEX Accumulation In Vivo Depends on Expression of ␣v␤3 of MMP-2 were found in media from bFGF-stimulated human umbilical vein endothelial cells (HUVECs) as deTo establish whether these MMP-2 fragments can be generated in an ␣v␤3-dependent manner in vivo, CS-1 tected by immunoblotting with MAb TV88 directed to melanoma tumors, which either express or lack ␣v␤3, were grown on the chorioallantoic membranes (CAMs) of chick embryos and examined for the presence of MMP-2 and its proteolytic fragments. Lysates from these tissues were then examined by Western blot analysis with MAb TV88, which recognizes the chick, human, or mouse C-terminal hemopexin-like domain. As shown in Figure 4A , whereas the host-derived proenzyme and active species were present in both tumor variants, significant quantities of PEX were only observed in ␣v␤3-bearing CS-1 tumor tissues. These findings show that the C-terminal hemopexin domain of MMP-2 corresponding to PEX can be generated in vivo in an ␣v␤3-dependent manner.
To determine whether PEX accumulation associated with the ␣v␤3-bearing tumors may be linked to a change in their angiogenic response, CS-1 tumors lacking or expressing ␣v␤3 were grown for 7 days on the CAM of 10-day-old embryos and photographed. As shown in Figure 4B , CS-1 tumors develop an extensive array of both large and small blood vessels. In contrast, ␣v␤3-bearing tumors are considerably smaller and show a reduced number of microvessels compared to CS-1 tumors lacking ␣v␤3. Therefore, not only does PEX accumulation depend on local expression of ␣v␤3, but its appearance is associated with decreased vascularization associated with these tumors.
PEX Accumulates during the Development of Retinal Blood Vessels
Murine retinal blood vessel development is initiated shortly before birth and proceeds for approximately 2 weeks postnatally (Friedlander et al., 1996) . During this period, ␣v␤3 is expressed on these vessels. In fact, antagonists of ␣v␤3 disrupt neovascularization in these tissues (Friedlander et al., 1996) . Extensive invasion of these superficial blood vessels occurs during the first tion and formation of a secondary vascular network as (A) Three groups of three separate randomly selected ␣v␤3-positive was previously described in the rat (Stone et al., 1995) . adult retina. However, when blood vessels begin to ma-(C) Retinas were harvested from postnatal mice at days 2, 4, 6, 8, ture in these tissues by days 5-6, the relative level of and 11 or adult mice, and lysed, and 25 g of each lysate was PEX increases to 13.5 fold over the level found in adult separated by SDS PAGE on 10% gels. Proteins were electroblotted and probed with MAb TV88 directed to PEX. The immunoreactive retina and shows a steady decline from day 8 to 11 as band corresponding to PEX was subjected to densitometric analysis neovascularization subsides (relative density 12 and 9.5, and the relative density compared to PEX found in the adult retina.
respectively). These findings demonstrate that PEX ac-
The kinetics of vessel invasion and maturation are depicted as bars cumulates during vessel invasion and reaches a maxibelow the figure. mal level during the maturation stage of retinal neovascularization, suggesting it acts as a negative regulator of the invasive stage of retinal neovascularization. regulate the invasive behavior of newly sprouting blood vessels. The fact that PEX can bind to ␣v␤3 and prevent MMP-2 collagenolytic activity in vitro raises the possibil-
PEX Disrupts Angiogenesis In Vivo
The accumulation of PEX in ␣v␤3-bearing tumors or ity that this fragment may be able to impact angiogenesis in vivo. To test this hypothesis, angiogenesis was during retinal neovascularization suggests that it may Angiogenesis was induced on the CAMs of 10-day-old chick embryos using a 5 mm filter disc saturated with recombinant bFGF placed on an area of the CAM that is relatively devoid of preexisting blood vessels. Equimolar (2 nmol) amounts of recombinant PEX or FHEX were added topically to the filter disc CAMs for 3 consecutive days. The CAM tissue associated with the filter disc was removed and photographed at 10ϫ on an Olympus stereomicroscope. induced with bFGF on the CAMs of 10-day chick emlevels of PEX found in extracts of retinal and tumor tissue were quantitatively determined by densitometric bryos, and PEX or FHEX was either added topically to the CAMs or injected systemically into these embryos.
comparison of band intensities. The level of PEX in the postnatal day 5-6 murine retina was approximately 109 As shown in Figure 5 , angiogenesis was induced within these CAMs directly below 5 mm filter discs coated pmol/mg of extracted tissues ( Figure 5D ). Postnatal days 5-6 represent the time retinal blood vessels cease with bFGF. This angiogenic response was specifically disrupted by addition of PEX but not FHEX ( Figure 5A ).
invading and begin to mature. In addition, ␣v␤3-bearing CS-1 tumors contained PEX at 21 pmol/mg, while CS-1 In fact, addition of 2 nmol of PEX resulted in Ͼ93% decrease in the angiogenic index as determined by enutumors lacking ␣v␤3 contained approximately 1 pmol/ mg (data not shown). The increased PEX in the ␣v␤3-merating the visible blood vessel branch points within the area of the filter discs ( Figure 5B ). Furthermore, this containing tumors correlated with a decrease in microvessel density in these tumors compared to CS-1 antiangiogenic effect was dose-dependent ( Figure 5C ).
tumors, which fail to express ␣v␤3 and do not produce significant levels of PEX ( Figure 4B ). We next added Physiologically Active Levels of PEX Can Be Detected at Sites of recombinant PEX to CAMs at a concentration shown to produce Ͼ90% inhibition of bFGF-induced angiogenNeovascularization In Vivo To establish whether the levels of PEX observed in vivo esis ( Figure 5C ). Extracts of these tissues were shown to contain approximately 750 pmol of PEX/mg tissue during neovascularization of tumors and in the developing retina reach physiological levels sufficient to influas determined above. However, based on the dosedependent effects of PEX on CAM angiogenesis as deence blood vessel formation or remodeling, PEX was quantified in extracts of these tissues by Western blot picted in Figure 5C , half-maximal inhibition of angiogenesis was achieved with the input of 10-fold less PEX, analysis using MAb TV-88 directed to PEX. A standard curve for PEX was obtained by immunoblotting known (i.e., 75 pmol/mg tissue). As shown in Figure 5D , this is within the range of PEX detected in the retinal tissue on amounts of recombinant PEX ( Figure 5D, inset) , and the was blocked by the addition of the metalloproteinase inhibitor 1:10 phenanthroline (data not shown). In addition, the serine protease inhibitor aprotinin, present in the lysis buffer, failed to impact this activity ( Figure 6A) . Importantly, addition of PEX but not FHEX to these CAMs during angiogenesis blocked the appearance of the 62 kDa gelatinolytic band ( Figure 6A ) as well as the associated collagenolytic activity ( Figure 6B ). PEX blocked this MMP-2 activity at 24, 48, and 72 hr after bFGF stimulation, even though new blood vessel formation in these tissues was not observed for approximately 48 hr after addition of bFGF. These findings suggest that the antiangiogenic effects of PEX are associated with its ability to block collagenolytic activity in vivo. Significant accumulation of this noncatalytic C-terminal domain may ultimately slow ongoing angiogenesis by reducing collagenolytic activity, thereby providing a negative feedback mechanism to limit neovascularization under certain physiological conditions.
PEX Disrupts Tumor Growth In Vivo
Angiogenesis contributes to the growth and dissemination of malignant tumors. Therefore, we examined the potential antitumor activity of recombinant PEX on ␣v␤3 negative CS-1 tumors grown on the CAMs of 10-dayold chick embryos. Embryos were injected systemically with either PEX or FHEX 24 hr after tumors were im- Figure 7C , PEX produced a 45% decrease in blood vesafter 36 hr of incubation. The MMP-2 collagenase activity was typically 2-3 fold over background levels.
sel density in these tumors relative to those treated with FHEX or PBS. Importantly, PEX had no effect on the in vitro growth rate of either ␣v␤3-positive or -negative day 5 (109 pmol/mg tissue), when the invasive stage of CS-1 tumor cells (data not shown), providing further neovascularization gives way to blood vessel maturasupport for the notion that the effects of PEX on these tion. These findings suggest that PEX accumulates durtumors are due to its antiangiogenic activity. ing neovascularization to levels that are physiologically relevant to influence blood vessel invasion, growth, and/ or remodeling. Discussion MMP-2 localizes in a proteolytically active form on the PEX Blocks Activation and Enzymatic Activity of MMP-2 In Vivo surface of invasive cells based on its ability to bind integrin ␣v␤3. Moreover, this interaction depends on the To address the possible mechanism by which PEX impacts the invasive behavior of blood vessels, we exam-C-terminal hemopexin-like domain of MMP-2, since a truncation mutant lacking this domain failed to interact ined the effects of PEX on MMP-2 enzymatic activity during angiogenesis in vivo, since this fragment blocked with ␣v␤3 (Brooks et al., 1996) . Therefore, we proposed that this functional cooperation between MMP-2 and cell-mediated collagenolytic activity in vitro (Figure 2) . Lysates of angiogenic CAM tissues were analyzed for ␣v␤3 facilitates invasive cell behavior by localizing proteolytic activity to discrete regions on the cell surface, MMP-2 activity by both gelatin zymography and collagen degradation. As shown in Figure 6A , bFGF inthereby potentiating angiogenesis and tumor metastasis (Brooks et al., 1996) . duced activation of MMP-2 in these CAM tissues within 24 hr as measured by the appearance of the 62 kDa In this report, evidence is provided that PEX blocks MMP-2 binding to ␣v␤3, resulting in a loss of cell-associgelatinolytic band. This 62 kDa band was confirmed to be active MMP-2 by Western blot analysis (data not ated collagenolytic activity. These findings are consistent with previously reported results indicating that the shown). The appearance of the 62 kDa active MMP-2 species was associated with increased collagen degrahemopexin domain of MMP-2 prevents cell-mediated MMP-2 activation (Strongin et al., 1993; Zucker et al., dation in these tissues ( Figure 6B ), and this collagenolytic activity was metalloproteinase-dependent since it 1995; Foda et al., 1996). Interestingly, the ability of Single cell suspensions of 3 ϫ 10 6 ␣v␤3-negative CS-1 tumor cells were applied to the CAMs of 10-day-old chick embryos. The embryos were injected intravenously with equimolar quantities of either recombinant PEX or FHEX 24 hr later. Tumors were allowed to grow for a total of 6 days, followed by resection and wet weight determination. , 1996) . Initial activation of MMP-2 is associated with proteofor this receptor (Cheresh et al., 1989) . At present, it is not clear whether the C-terminal domain of MMP-2, lytic processing of the intact 72 kDa enzyme, leading to the autocatalytic removal of the 80 amino acid prodotermed PEX, is the only region of this enzyme that binds ␣v␤3. However, MMP-2 binding to ␣v␤3 may depend on main, resulting in the 62 kDa active form (Ward et al., 1991; Fridman et al., 1992; Strongin et al., 1995) . It has a tertiary structure since the larger C-terminal fragment, termed FHEX, containing PEX as well as the flexible been suggested that in the absence of TIMP-2, this active 62kDa form can be further processed to a 43 kDa hinge domain and the third type II fibronectin repeat, binds poorly to ␣v␤3. active species resulting from autocatalytic removal of the 29 kDa hemopexin-like domain (Howard et al., 1991) . Systemic administration of recombinant PEX blocked collagenolytic activity in vivo, leading to a significant This C-terminal domain of MMP-2 appears to be the same fragment that we identified as PEX as detected reduction in the growth of CS-1 melanoma tumors grown on the CAMs of chick embryos. This effect was related with MAb TV88 generated to the recombinant form of this molecule. This antibody served to identify PEX in to its capacity to significantly reduce angiogenesis in these tumors. Importantly, these CS-1 melanoma tuextracts of ␣v␤3-bearing CS-1 tumors and during retinal blood vessel development, suggesting that ␣v␤3 exmors lack functional expression of integrin ␣v␤3 and produce little if any endogenous MMP-2 (Brooks et al., pression contributes to the generation of this fragment in vivo. 1996), providing further evidence that the observed inhibition of tumor growth is due to the suppression of Integrin ␣v␤3 expression on tumors was associated with decreased angiogenesis and, accordingly, the tumor-associated angiogenesis. In fact, PEX did not influence the growth rate of these cells in vitro, supporting production of PEX to levels within the physiological range required for angiogenesis inhibition. Importantly, the notion that the antitumor activity of PEX is due to its antiangiogenic effects. Moreover, since PEX blocks PEX was shown to accumulate in retinal membranes undergoing developmental neovascularization. While collagenolytic activity both in vitro and in vivo, it is likely that the antiangiogenic effects of PEX are related to its PEX was first detected during the invasive stage of retinal neovascularization, its level reached a maximum durability to block collagenolytic activity. This contention is supported by previous studies demonstrating the abiling the maturation stage of new blood vessels and was only minimally detectable in the adult retina. The fact ity of naturally occurring tissue inhibitors of metalloproteinase (TIMPs) to inhibit angiogenesis (Moses et al., that PEX blocks ␣v␤3-directed MMP-2 activity and disrupts angiogenesis suggests that its accumulation dur-1990; Galardy et al., 1994; Anand-Apte et al., 1997). In fact, the balanced expression of both TIMPs and MMPs ing blood vessel maturation would allow it to provide a feedback mechanism to prevent inappropriate blood could provide a mechanism whereby matrix degradation RTet al., 1994; Cao et al., 1996; Foda et al., 1996) . Therefore, PCR and used as a template for amplification of PEX and FHEX. it is possible that MMP-2 binds to MT-MMP on the cell Products were digested and ligated into pGEX-3X plasmid (Pharsurface and becomes partially activated whereby it then macia Biotech, Uppsala, Sweden), and GST fusion proteins were purified from IPTG-induced log phase bacterial cultures containing becomes capable of binding ␣v␤3. This is an attractive these constructs on Sepharose 4B-coupled glutathione beads hypothesis since it suggests that only the active form cell-targeted collagenase activity important for cell invasion (Brooks et al. 1996) , which likely depends on the Purified Receptor Binding Assay ability of ␣v␤3 to bind selectively proteolyzed fragments GST fusion proteins and full-length MMP-2 were iodinated acof collagen leading to signals required for cell survival cording to the manufacturer's instructions for IODO-Beads reagent (Montgomery et al. 1994) . Second, ␣v␤3 facilitates cleav-(Pierce, Rockford, IL). Unconjugated [ 125 I] was removed, and recovage of this enzyme and accumulation of a noncatalytic ered radiolabeled proteins were resuspended in PBS, quantified, and specific activity determined. Immulon-4 multichamber strips fragment that inhibits cell invasion. Accordingly, the ap- were diluted in collagenase binding buffer (50 mM Tris, 200 mM NaCl, 0.05 mM CaCl 2, 0.2 mM MnCl2, 0.5% protease free BSA [pH 8.0]) and added to the wells (50 l/well) for 1 hr incubation at 37ЊC.
Experimental Procedures
Wells were washed 4ϫ with binding buffer, separated, and binding was quantified with a 1282 Compugamma CS Universal counter Antibodies and Reagents (LKB Wallac, Gaithersburg, MD) . Values were corrected for nonspePolyclonal and monoclonal antibodies directed to MMP-2 were kind cific binding to BSA control wells. gifts from Dr. W. G. Stetler-Stevenson (National Institute of Health, For antibody-based detection of intact MMP-2 binding to ␣v␤3, Bethesda, MD). MAb LM609, anti-␣v␤3 has been previously deassays were performed essentially as described previously (Brooks scribed (Cheresh and Spiro, 1987) . MAb TV88, directed to avian PEX, et al., 1996) . In brief, sterile ELISA plates (Corning Glass Works, was generated by fusion of SP-20 myeloma cells with splenocytes Corning, NY) were coated with purified integrin ␣v␤3 (1 g/ml) and derived from female Balb/C mice injected intraperitoneally (6 times blocked as above before addition of inhibitors at a 2ϫ concentration. over 3-4 weeks) with purified recombinant chick C-terminal hemo-MMP-2 in collagenase binding buffer (final concentration 30 nM) pexin domain (PEX) fusion protein coupled to glutathione beads.
was added and incubated for 90 min at 37ЊC. After washing, antiReactive hybridomas were subcloned, and TV88 (IgG1k) was shown MMP-2 polyclonal antibody was incubated for 90 min at 37ЊC before to react with chick, mouse, and human forms by immunoblotting.
further washing and 90 min incubation at 37ЊC with HRP-conjugated Recombinant chick MMP-2 was generously provided by Dr. James goat anti-rabbit secondary antibody (BioSource International, CaQuigley (State University of New York at Stonybrook, Stonybrook, marillo, CA). Binding was visualized by color development with OPD NY) and has been described previously (Aimes et al., 1994) . Recomsubstrate and absorbance determination at 490 nm. Optical density binant human MMP-2 was obtained from Chemicon (Temecula, CA).
values were corrected for nonspecific binding to BSA-blocked Integrin ␣v␤3 was purified from placental tissue as described (Smith ␤-casein. et al., 1990) .
[ 3 H]-Collagen Type IV Degradation Assay
Collagen type IV degradation assays were performed as described Cell Lines CS-1 hamster melanoma cells lacking ␣v␤3 and ␣v␤5 were provided previously, with minor modifications (Brooks et al. 1996) . For cellmediated collagen degradation assays, 2 ϫ 10 6 CS-1 or ECV304 by Dr. C. Damsky (University of California, San Francisco, CA). CS-1 cells transfected with a ␤3 integrin subunit cDNA were described cells were preincubated for 3.5 hr at 37ЊC with 500 ng/ml of recombinant MMP-2 in a total volume of 500 l of fibroblast basal medium previously (Filardo et al., 1995 for 12 hr at 37ЊC in collagenase buffer. Gelatinolytic activity was visualized by staining the gels with 0.5% Coomassie blue. degradation was assessed as the cpm released per 50 l of medium at 16 and 36 hr corrected for the cpm released from buffer-only wells. For CAM lysate collagen degradation assays, three chick Acknowledgments CAMs from each experimental condition were combined and homogenized on ice for 10 min in 500 l lysis buffer (50 mM Tris, 200 The authors wish to thank Drs. J. Quigley, E. Hahn, and W. G. StetlermM NaCl, 10 mM CaCl2, 1.0% Triton X-100, 10 g/ml Aprotinin).
Stevenson for providing MMP-2 fusion proteins, cDNAs, and/or antiLysates were centrifuged to remove insoluble material and probodies. We thank Dr. J. Abraham, of Scios Pharmaceuticals, for cessed as above.
generously providing bFGF used in these studies. This work was supported by National Institutes of Health grants HL54444, CA50286, and CA45726 to D. A. C. and N. E. I. grant EY11254 to M. F. P. C. B.
Western Blot Analysis
was supported by training grants T32 AI 07244-11 and R29-CA74132 Immunoblotting was performed essentially as described previously and S. S. was supported by fellowship F32-CA72192. This is TSRI (Brooks et al., 1996) . For analysis of purified recombinant chick manuscript number 11045-IMM. MMP-2, enzyme was activated with APMA as described above and coelectrophoresed alongside the starting material before electroblotting and incubation with anti-MMP-2 polyclonal antibody. PriReceived August 4, 1997; revised January 5, 1998. mary antibody was detected with HRP-conjugated goat anti-rabbit secondary antibody (BioSource International) and visualized as References below.
For tissue analysis, murine retinas were harvested at postnatal Aimes, R.T., French, D.L., and Quigley, J.P. (1994) . Cloning of a days 2, 4, 6, 8, 11, and adult (Friedlander et al., 1996) , and tumor 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo lysates (50 g/lane) were obtained from pooled homogenates of fibroblasts using gene family PCR: expression of the gelatinase three randomly selected CS-1 or ␤3CS-1 tumors (9 tumors each in increases upon malignant transformation. Biochem. J. 200, 729-736. 3 groups of 3), which had been grown in the absence of treatment Anand-Apte, B., Pepper, M.S., Voest, E., Montesano, R., Olsen, B., for 7 days on the chick CAM as described above. Samples were Murphy, G., Apte, S.S., and Zetter, B. (1997 
Tumor Growth Assays
Ten-day-old chick embryos were prepared as previously described Brooks, P.C., Montgomery, A.M.P., Rosenfeld, M., Reisfeld, R.A., (Brooks et al., 1995) , and either 5 ϫ 10 6 ␣v␤3-positive or -negative Hu, T., Klier, G., and Cheresh, D.A. (1994b) . Integrin ␣v␤3 antagonists CS-1 tumor cells (for morphology assessment) or 3 ϫ 10 6 CS-1 promote tumor regression by inducing apoptosis of angiogenic melanoma cells (for growth inhibition assay) were inoculated onto blood vessels. Cell 79, 1157-1164. the CAMs of these embryos. For the tumor growth inhibition assay, Brooks, P.C., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F.H., embryos were incubated 24 hr prior to systemic injection with 1 and Cheresh, D.A. (1995) . Antiintegrin ␣v␤3 blocks human breast nmol of either PEX or FHEX in a total volume of 100 l while tumor cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, morphology embryos were left untreated. Embryos were further 1815-1822. incubated for a total of 7 days and sacrificed, and primary tumors Brooks, P.C., Stromblad, S., Sanders, L.C., von Schalscha, T.L., were resected before photographing and determination of wet Aimes, R.T., Stetler-Stevenson, W.G., Quigley, J.P., and Cheresh, weights. Treated tumors were snap-frozen, sectioned, and acetone- D.A. (1996) . Localization of matrix metalloproteinase MMP-2 to the fixed prior to immunofluorescent staining with a MAb antibody to surface of invasive cells by interaction with integrin ␣v␤3. Cell 85, factor VIII-related antigen (BioGenex, San Ramon, CA). Blood vessel 683-693. quantitation was assessed as the number of vessels per high power Cao, J., Rehemtulla, A., Bahou, W., and . Membrane field (200ϫ magnification, 10 fields/condition) at the tumor petype matrix metalloproteinase 1 activates pro-gelatinase A without riphery.
furin cleavage of the N-terminal domain. J. Biol. Chem. 271, 30174-30180.
Chick CAM Angiogenesis Assay
Cheresh, D.A., and Spiro, R.C. (1987) . Biosynthesis and functional Angiogenesis assays were performed essentially as described with properties of Arg-Gly-Asp-directed receptor involved in human melminor modifications (Brooks et al, 1994b) . Filter discs saturated with anoma cell attachment to vitronectin, fibrinogen and von Willebrand 1.0 g/ml bFGF were placed on the CAMs of 10-day-old chick factor. Proc. Natl. Acad. Sci. USA 84, 6471-6475. embryos, immediately followed by daily topical addition of PEX or FHEX (2 nmol) in 20 l of FBM. For systemic administration, PEX Cheresh, D.A., Berliner, S.A., Vicente, V., and Ruggeri, Z. (1989) . and FHEX were injected intravenously in a total of 100 l of sterile Recognition of distinct adhesive sites on fibrinogen by related inte-PBS 24 hr after CAM stimulation with bFGF. After 72 hr, filter discs grins on platelets and endothelial cells. Cell 58, 945-953. and associated CAM tissue were harvested and quantified. Angio-D'Amore, P.A., and Thompson, R.W. (1987) . Mechanisms of angiogenesis was assessed as the number of visible blood vessel branch genesis. Annu. Rev. Physiol. 49, 453-464. points within the defined area of the filter discs. The angiogenic DeClerck, Y.A., and Laug, W.E. (1996) . Cooperation between matrix index represents the mean treated branch points corrected for metalloproteinase and the plasminogen activator-plasmin system branching observed in the absence of stimulation.
in tumor progression. Enz. Prot. 49, 72-84.
Filardo, E.J., Brooks, P.C., Deming, S.L., Damsky, C., and Cheresh, Gelatin Zymography D.A. (1995) . Requirement of the NPXY motif in the integrin ␤3 subunit Gelatin zymography was performed as previously described with cytoplasmic tail for melanoma cell migration in vitro and in vivo. J. minor modifications (Brooks et al. 1996) . Briefly, 25 or 50 g of Cell Biol. 130, 441-450. total CAM lysates was electrophoresed on a 8% polyacrylamide gel containing 0.2% EIA grade gelatin (BioRad, Hercules, CA). Gels were Foda, H.D., George, S., Conner, C., Drews, M., Tompkins, D.C., and
